Back to Journals » Cancer Management and Research » Volume 10

Predictive biomarkers for tumor immune checkpoint blockade

Authors Tong M, Wang J, He W, Wang Y, Pan H, Li D, Zhang H

Received 10 July 2018

Accepted for publication 20 August 2018

Published 11 October 2018 Volume 2018:10 Pages 4501—4507

DOI https://doi.org/10.2147/CMAR.S179680

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 2

Editor who approved publication: Dr Beicheng Sun


Mengting Tong,1,2,* Jing Wang,2,* Wenting He,1 Yanling Wang,2 Hongming Pan,2 Da Li,2 Hongliang Zhang1

1Second Department of Medical Oncology, The Fourth Affiliated Hospital of Xinjiang Medical University, Saybagh District, Urumqi, Xinjiang 830000, People’s Republic of China; 2Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Jianggan District, Hangzhou, Zhejiang 310016, People’s Republic of China

*These authors contributed equally to this work

Abstract: The development of immune checkpoint inhibitors represented by PD-1 and PD-L1 has provided new hope for the treatment of advanced cancer patients. However, there are no effective predictive biomarkers, which have caused many limitations to the clinical application of immune checkpoint inhibitors. This paper combines recent domestic and international research as well as clinical trials to discuss the current status and progress of PD-L1 expression as a biomarker for tumor immunotherapy and also to discuss whether tumor mutation burden, tumor-infiltrating lymphocytes, tumor cell gene expression profiling, or peripheral blood markers would be a potential predictive biomarker for novel tumor immunotherapy. So, a brief review on this hot topic of predictive biomarkers for tumor immunotherapy is conducted.

Keywords: immunotherapy, immune checkpoint inhibitors, predictive biomarker

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]